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ABSTRACT
Healthcare systems worldwide are responding to Coronavirus Disease 2019 
(COVID-19), an emerging infectious syndrome caused by the Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. Patients with 
COVID-19 can progress from asymptomatic or mild illness to hypoxemic 
respiratory failure or multisystem organ failure, necessitating intubation and 
intensive care management. Healthcare providers, and particularly anesthe-
siologists, are at the frontline of this epidemic, and they need to be aware 
of the best available evidence to guide therapeutic management of patients 
with COVID-19 and to keep themselves safe while doing so. Here, the authors 
review COVID-19 pathogenesis, presentation, diagnosis, and potential ther-
apeutics, with a focus on management of COVID-19–associated respiratory 
failure. The authors draw on literature from other viral epidemics, treatment 
of acute respiratory distress syndrome, and recent publications on COVID-19, 
as well as guidelines from major health organizations. This review provides a 
comprehensive summary of the evidence currently available to guide manage-
ment of critically ill patients with COVID-19.
(ANESTHESIOLOGY 2020; XXX:00–00)
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In December 2019, a novel pneumonia syndrome was iden-tified in patients clustered around the Huanan Seafood 
Market in Wuhan, China.1,2 Next generation sequencing 
was used to identify a novel coronavirus, now known as 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2), in bronchoalveolar lavage fluid from three of these 
patients. Infection with SARS-CoV-2 leads to the syndrome 
of Coronavirus Disease 2019 (COVID-19). Rapid interna-
tional spread of this potentially lethal virus has caused global 
concern, with 110,000 cases and 3,800 deaths reported to 
date.2,3 Here, we will summarize the latest insights into the 
biology of SARS-CoV-2 and their implications for anesthe-
siologists in perioperative and intensive care settings.
COVID-19 Pathogenesis
Relative to the assortment of viruses that cause human 
upper respiratory tract infection, the group of viruses 
that cause lower respiratory tract infection is smaller, but 
includes influenza and parainfluenza, respiratory syncytial 
virus, cytomegalovirus, and hantavirus. These infections are 
mostly limited to tracheobronchitis in healthy individuals 
but can cause severe viral pneumonias in immunocompro-
mised patients. While influenza is one of the best-known 
causes of pneumonia in the intensive care unit (ICU), this 
presentation is frequently related to bacterial superinfec-
tion, such as with Staphylococcus aureus.4 Some of the rar-
ity of viral pneumonia can be attributed to the types of 
cells that viruses can infect, termed tropism. Thus, while the 
more common influenza strains (like H1N1) target cells in 
the trachea and bronchi, influenza pneumonia is particu-
larly linked to avian strains (like H5N1) that skip the upper 
respiratory epithelium and infect alveolar epithelial cells of 
the lower respiratory tract.5
SARS-CoV-2 is a beta-coronavirus, a family that includes 
the original severe acute respiratory syndrome (SARS) virus, 
as well as Middle East respiratory syndrome-related coro-
navirus (MERS), and endemic human pathogens that are 
common causes of the cold, including OC43 and HKU1. 
While beta-coronaviruses have been around for more than 
5,000 yr, outbreaks of lethal strains of SARS-CoV in 2002 
and Middle East respiratory syndrome-related coronavi-
rus in 2012 have added to their notoriety.6 SARS-CoV, 
Middle East respiratory syndrome-related coronavirus, and 
SARS-CoV-2 all likely originated in bats, with SARS-CoV 
using civets as intermediary hosts and Middle East respi-
ratory syndrome-related coronavirus passing though cam-
els. Pangolins, also known as scaly anteaters, are implicated 
in the passage of SARS-CoV-2 to humans on the basis of 
sequence similarity with pangolin coronaviruses.7
The variable clinical manifestations caused by distinct 
coronavirus strains can be attributed to structural differences 
in virus proteins, affecting tropism and replication. The 
“corona” description references the crown-like halo of viral 
spike (S) proteins observed by electron microscopy (fig. 1). 
Variations in this S-protein determine which proteins 
coronavirions use to enter cells. Early investigations into 
SARS-CoV-2 suggest that it uses tissue angiotensin con-
verting enzyme-2 as its receptor, a trait shared with SARS, 
but not Middle East respiratory syndrome-related coronavi-
rus or more common endemic human coronaviruses such 
as OC43 and HKU1.8,9 Angiotensin converting enzyme-2 
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is expressed in the lower respiratory tract but not bronchi, 
as well as enterocytes in the small intestine.10 Thus, angio-
tensin converting enzyme-2 dependence may explain the 
clinical presentations of lower respiratory tract infection and 
enteritis in COVID-19. Angiotensin converting enzyme-2 
expression in vascular endothelium and cardiac myocytes 
has also been implicated in acute cardiac injury resulting 
from COVID-19.11 In animal models, angiotensin convert-
ing enzyme inhibitors and angiotensin-receptor blockers 
increase angiotensin converting enzyme-2 expression and 
activity, respectively, leading to speculation that these medi-
cations could possibly potentiate SARS-CoV-2 infection.12 
Major cardiology societies do not recommend changing 
renin angiotensin aldosterone system antagonist treatments 
based on COVID-19 risk at this time.13 Other sites express 
angiotensin converting enzyme-2, such as the tongue and 
parts of the genitourinary tract, but the clinical signifi-
cance of this finding in COVID-19 is unclear.14 Binding of 
S-protein to angiotensin converting enzyme-2 likely con-
tributes directly to pathogenesis, resulting in downregulation 
of angiotensin converting enzyme-2, increased production 
of angiotensin II, and resulting increased pulmonary vascu-
lar permeability.15 While SARS-CoV-2–susceptible angio-
tensin converting enzyme-2 appears universally expressed in 
humans, there may be genetic variations regulating angioten-
sin converting enzyme-2 expression that could lead to dif-
ferential susceptibilities across populations and genotypes.16
After viral binding to angiotensin converting enzyme-2, 
the virus may be endocytosed or directly fuse with the cell 
membrane (fig. 2). A positive-sense viral RNA transcript is 
then translated by the host cell, yielding two polypeptides. 
These polypeptides are subsequently divided by viral prote-
ases, yielding the viral replication machinery. Coronaviruses 
employ multiple mechanisms to shield viral RNA from host 
detection and subsequent induction of antiviral interferon 
responses, including direct antagonism of interferon signaling 
proteins and replication of viral RNA in double membrane 
vesicles.15 Nonetheless, COVID-19 strongly induces cyto-
kines and chemokines including interleukin-2, interleukin-4, 
interleukin-7, interleukin-8, interleukin-10, interferon-ɣ, 
tumor necrosis factor-ɑ, and macrophage inflammatory 
protein-1-ɑ, suggesting a broad type 1 and type 2 helper 
T-cell response.17 It remains uncertain to what extent direct 
viral cytotoxicity versus the host cytokine storm and other 
immune responses contributes to morbidity in COVID-19.
After initial coronavirus infection, immune responses 
appear effective in controlling viral infection, suggesting 
that vaccines should be feasible. There were important 
caveats from animal vaccine models: antibody responses 
waned quickly, indicating that immune responses might not 
be long-lasting.18 Also, in one mouse coronavirus model of 
SARS, natural killer cell, antibody, and interferon responses 
were beneficial, but T-cell responses paradoxically worsened 
outcomes.19 Accordingly, vaccines will need to demonstrate 
safety and effectiveness before widespread adoption.
COVID-19 Typical Presentation and Diagnosis
The incubation period for SARS-CoV-2 appears to be from 
4 to 7 days. Initial reports demonstrated rapid person-to-per-
son viral transmission, with the number of infected individu-
als doubling every 7.4 days.20 Viral evolution patterns inferred 
from viral gene sequence variations suggest that much of the 
viral transmission that has occurred in the United States has 
been undiagnosed, where two cases reported 6 weeks apart 
could potentially represent a cluster of hundreds of infec-
tions.21 Two distinct groups of SARS-CoV-2 sequences have 
been identified: The L-type represented 96% of the cases in 
Wuhan, while the more ancestral S-type was found in 38% 
of cases outside Wuhan. It has been postulated that the S-type 
could be less severe and thus capable of more rapid spread 
because of less negative selective pressure.7
The majority of patients with COVID-19 infection 
present with fever as the first symptom. Other common 
symptoms at onset of illness include cough or fatigue. 
Less commonly reported symptoms include palpitations, 
headache, and diarrhea. A subset of patients develop dys-
pnea at days 5 to 8 after hospitalization. The most com-
monly reported hematologic laboratory abnormalities with 
COVID-19 are leukopenia and lymphopenia.17,22–24 The 
cause of this leukopenia is not well understood but could 
relate to bone marrow suppression, lymphocyte sequestra-
tion, or apoptosis.25 The clinical spectrum of COVID-19 
Fig. 1. SARS-CoV-2 virus particles visualized by transmission 
electron micrograph. Viral particles are shown in blue-green with 
yellow viral envelope. This image was captured and color-en-
hanced at the National Institute of Allergy and Infectious Diseases 
Integrated Research Facility (Fort Detrick, Frederick, Maryland) 
and used under creative commons license agreement.107
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cases has ranged from asymptomatic to critically ill.23 While 
the majority of patients have mild symptoms and good prog-
nosis, up to 15% of patients will develop pneumonia, acute 
respiratory distress syndrome (ARDS), cardiac injury, renal 
injury, or multiorgan failure from days 7 to 10 after hospi-
talization. A subset of patients with COVID-19 will require 
admission to the ICU and respiratory support with nonin-
vasive or invasive ventilation, or potentially extracorporeal 
membrane oxygenation.17,22–24 A summary of COVID-19 
symptoms, complications, and treatment in the initial wave 
of case series publications is presented in table 1.
Of concern to anesthesiologists in the perioperative 
setting, some patients present with minimal respiratory 
symptoms. In one of the initial case series, a patient with 
abdominal symptoms was admitted to a surgical service 
and infected at least 10 healthcare providers.24 Abdominal 
symptoms of COVID-19 may reflect angiotensin con-
verting enzyme-2 expression in the small intestine and are 
potentially underappreciated, since patients with gastro-
intestinal symptoms may not be tested for SARS-CoV-2. 
Indeed, SARS-CoV-2 may be transmitted via the fecal–oral 
route via contaminated surfaces.26
Pneumonia or abnormalities in chest computed tomog-
raphy images were detected in almost all hospitalized 
patients with COVID-19. The characteristic radiographic 
findings are ground glass opacities, which are typically bilat-
eral and peripheral, coexisting with consolidations or cord-
like opacities.17,27,28 As COVID-19 progresses, “reverse halo” 
or “crazy-paving” radiologic patterns may become apparent. 
Notably, some radiologic features are rare with COVID-19, 
such as lymphadenopathy, nodules, pleural effusions, or cav-
itation, and would potentially suggest other pathologies.28
For diagnosis of SARS-CoV-2, reverse transcrip-
tase-polymerase chain reaction testing is the standard assay. 
Throat swab and nasal swab samples are commonly used 
for reverse transcriptase-polymerase chain reaction. While 
reverse transcriptase-polymerase chain reaction is a useful test 
to confirm the diagnosis of COVID-19, with limitations of 
sample collection and kit performance, the total positive rate 
of reverse transcriptase-polymerase chain reaction for throat 
swab samples has been reported to be about 30 to 60% at 
initial presentation.29 Serial reverse transcriptase-polymerase 
chain reaction testing and inclusion of lower airway sam-
pling can improve the sensitivity of testing. Commercially 
Fig. 2. Coronavirus biology. Notable coronavirus structural proteins include the spike protein (S), which mediates receptor binding and 
fusion, the viral membrane protein (M), and the nucleocapsid protein (N). After binding of the viral spike protein to the angiotensin converting 
enzyme-2 (ACE2) receptor, virions enter cells either by receptor-mediated endocytosis or direct fusion with the cell membrane.15 Endocytosis 
is a potential target of chloroquine, which prevents endosomal acidification that triggers viral membrane fusion. Chloroquine may also modify 
ACE2 terminal glycosylation and inhibit coronavirus binding. Viral RNA is then transcribed to generate polyproteins pp1a and pp1ab that are 
cleaved by a protease to generate the viral replication machinery. These polyproteins are cleaved to form replication-transcription protein 
complexes (RTCs) by a viral protease 3-chymotrypsin-like protease (3CLpro). 3CLpro has been postulated to be a target of human immu-
nodeficiency virus protease inhibitors lopinavir or ritonavir, although in silico studies have questioned this theory.108 Viral RNA is replicated 
and transcribed in double membraned vesicles (DMV) in replication-transcription protein complexes, which include the RNA-dependent RNA 
polymerase that is the putative target of remdesivir. Viral mRNA is then translated and virions are assembled in the endoplasmic reticulum 
and golgi.
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available molecular tests for endemic coronaviruses, such 
as the FilmArray Respiratory Panel (BioFire Diagnostics, 
USA) do not detect SARS-CoV-2 currently. It is expected 
that SARS-CoV-2 will be added soon.30 Chest computed 
tomography may have higher sensitivity for COVID-19 
infection, with a sensitivity as high as 97% in one study.29 
Based on challenges with reverse transcriptase-polymerase 
chain reaction testing, computed tomography imaging has 
been proposed as a primary tool for COVID-19 detection 
in hospitalized patients in epidemic areas. However, within 
the first 2 days after symptom onset, the majority of patients 
may have normal computed tomography imaging.28 Thus, 
early in the disease course, there may be no diagnostic suffi-
ciently sensitive to exclude COVID-19.
Pathology findings of COVID-19 have been reported 
in some cases.31,32 While many of the pathologic findings 
are similar to those seen with coronavirus-associated severe 
acute respiratory syndrome caused by SARS-CoV and 
Middle East respiratory syndrome–related coronavirus, such 
as inflammatory infiltrates and hyaline membrane formation, 
the findings of inspissated spherical secretions or fibromyx-
oid exudates are more prominent in COVID-19 infec-
tion. Accumulation of these thick secretions likely causes 
decreased alveolar gas exchange predisposing to respiratory 
failure, suggesting a potential role for airway clearance and 
bronchial hygiene in the treatment of COVID-19.
The full ramifications of SARS-CoV-2 infection are yet 
to be understood. Early work points to a wide variety of 
psychiatric complications affecting patients, their families 
and providers, and larger communities relating to anxi-
ety, isolation, frustration, stigma, and guilt.33 This disease 
also poses increased risk to specific subpopulations, such 
as transplant candidates and recipients,34 and patients with 
cancer.35
Variation in COVID-19 Presentations
As highlighted in published case series, there is wide vari-
ation in clinical presentations of COVID-19, ranging from 
no symptoms to intractable ARDS and shock. The deter-
minants of these varied outcomes remain unknown, but 
experience with other viruses suggests that variation in the 
dose of viral inoculum, route of inoculation, and underlying 
immune status of the patient can lead to widely variable 
host responses.36 Higher viral loads on random sampling 
identified individuals with greater symptom burden in 
influenza37 and greater mortality in adenoviral pneumo-
nia.38 At the same time, moderate SARS-CoV-2 viral 
loads can be detected in nasal swabs up to 2 weeks after 
the onset of symptoms and in asymptomatic individuals.39 
The attributable risk from higher viral inocula is difficult 
to quantify in real-world settings, but higher viral loads in 
critically ill patients pose at least a theoretical risk to health-
care providers.40
The major risk factors for mortality among early 
reported cases of COVID-19 are old age and underlying 
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respiratory disease.24 Again, the reasons for these age asso-
ciations are unknown, but there are multiple theories 
that can be extrapolated from host–pathogen biology. 
For example, immunosenescence could contribute to the 
increased risk among the aged. As individuals age, the fre-
quency of naive B and T cells diminishes, implying less 
capacity to recognize and adapt to novel antigens. At the 
same time, aged immune cells have less proliferative and 
functional capacity even when responding to known anti-
gens. Such age-related changes in cellular immunity man-
ifest in decreased vaccine effectiveness, worse outcomes 
in the setting of influenza, respiratory syncytial virus, and 
herpes zoster infections,41 and have been demonstrated 
in mouse models of coronavirus infection.18 As the lung 
ages, the airway epithelium restorative capacity is also 
diminished. Telomere dysfunction is one biologic mech-
anism of aging, which primarily manifests as pulmonary 
fibrosis but can also restrict leukocyte proliferation. It is 
conceivable that poor outcomes from COVID-19 could 
be linked to short telomeres, as has been reported with 
pulmonary fibrosis, ARDS, and sepsis.42,43 It is also pos-
sible that younger individuals may have differential sus-
ceptibility to SARS-CoV-2. Interestingly, in the rat lung, 
angiotensin converting enzyme-2 expression decreases 
with age.44 Children also could benefit from immunity 
developed from other coronavirus infections. Indeed, 
modest cross-reactivity was observed between endemic 
coronaviruses, such as OC43 and SARS-CoV.45 This 
potentially protective cross-reactive immunity would be 
limited by age and immunosenescence. If fecal–oral trans-
mission resulted in a milder gastroenteritis presentation of 
SARS-CoV-2, it is also conceivable that children could be 
subsequently protected from the COVID-19 respiratory 
syndrome. While we currently can only speculate as to 
the causes of variation in COVID-19 presentations, these 
mechanisms likely hold important clues that will inform 
management and therapeutics.
Management of COVID-19–associated  
Respiratory Failure
While most patients with COVID-19 appear to have a rel-
atively mild disease course, a subset will develop hypoxemic 
respiratory failure with imaging patterns consistent with 
diffuse viral pneumonitis, organizing pneumonia, or diffuse 
alveolar damage.28,46 The true incidence of severe pulmo-
nary disease associated with SARS-CoV-2 is not yet clear, 
but several studies from Hubei province have reported a 
5 to 25% ICU admission rate among hospitalized patients 
with confirmed SARS-CoV-2, and an ARDS diagnosis in 
60 to 70% of patients admitted to the ICU (table  1).24,47 
Among patients who do develop dyspnea and hypoxemia, 
the median time from onset of symptoms to the develop-
ment of dyspnea appears to be between 5 and 8 days, with 
ARDS developing in a smaller subset of those patients at 7 
to 10 days.24,47,48
The management of severe hypoxemia in COVID-19 is 
drawn from the management of ARDS and also informed by 
experience during the 2003 SARS-CoV and 2012 Middle 
East respiratory syndrome–related coronavirus outbreaks. 
The World Health Organization has published a practice 
guideline on the clinical management of COVID-19 severe 
respiratory infection,49 and several other groups have also 
published practice recommendations for the care of patients 
with COVID-19–associated ARDS.50–53 The treatment of 
patients with COVID-19–associated ARDS is made more 
complex due to necessary infection control interventions 
such as the use of isolation rooms and the need for care pro-
viders to wear appropriate personal protective equipment. 
Transmission of SARS-CoV-2 from patients to healthcare 
workers has been reported, and infection control is of pri-
mary importance to protect healthcare workers and pre-
vent further spread of SARS-CoV-2.24,54 The World Health 
Organization guideline recommends, in addition to routine 
standard precautions, that providers use droplet and contact 
precautions when caring for any patients with confirmed or 
suspected SARS-CoV-2 infection, with the addition of air-
borne precautions when any aerosol-generating procedure, 
such as intubation, bronchoscopy, suctioning, or cardiopul-
monary resuscitation, is performed.49 Additional guidelines 
and frontline reports from groups in Hubei province sug-
gest many providers are utilizing airborne precautions at all 
times while caring for COVID-19 patients as an additional 
safety measure.50,51
In select patients with COVID-19–associated respiratory 
failure presenting with hypoxemia that is not adequately 
treated with low flow nasal cannula oxygen or conventional 
facemask, a trial of either noninvasive positive pressure ven-
tilation or heated and humidified high flow nasal cannula 
oxygen may be reasonable before endotracheal intubation 
and mechanical ventilation.49 World Health Organization 
COVID-19 management guidelines, among others, suggest 
this trial should be of limited duration (1 h) to avoid unrec-
ognized severe respiratory decompensation that requires 
emergent intervention. The use of high flow nasal cannula 
or noninvasive positive pressure ventilation is contraindi-
cated in patients with hemodynamic instability, multiorgan 
failure, or altered mental status.49,50
High flow nasal cannula can provide 100% oxygen to 
patients at a high flow rate, adds a low (2 to 3 cm H
2
0) 
positive end-expiratory pressure (PEEP) effect, and reduces 
the work of breathing in patients with acute respiratory 
failure.55,56 High flow nasal cannula has been used to treat 
ARDS with a good safety profile, but given its more recent 
clinical introduction, there are little data from other out-
breaks to guide its use in COVID-19 associated respira-
tory failure.49,57 In one study of 310 patients with ARDS 
randomized to receive initial high flow nasal cannula, 
noninvasive positive pressure ventilation, or conventional 
oxygen therapy, the use of high flow nasal cannula did not 
significantly reduce intubation rates overall, but patients 
Copyright © 2020, the American Society of Anesthesiologists, Inc. Unauthorized reproduction of this article is prohibited.
6 Anesthesiology 2020; XXX:00–00 Greenland et al.
SPECIAL SECTION: COVID-19
randomized to the high flow nasal cannula arm had a lower 
90-day mortality rate.58 Patients with moderate or severe 
ARDS were less likely to require conversion to mechanical 
ventilation when randomized to the high flow nasal can-
nula arm of this trial.58 A systematic review of the use of 
high flow nasal cannula in ARDS did not find a difference 
in mortality or intubation rates as compared with usual care, 
and found that high flow nasal cannula is well tolerated by 
patients.57 The use of novel indices, such as the ratio of oxy-
gen saturation/fraction of inspired oxygen to respiratory 
rate, may be helpful to predict clinical deterioration and the 
need for intubation when high flow nasal cannula is used.59
Given the existing literature base, the use of high flow 
nasal cannula as an initial strategy for the treatment of 
COVID-19–associated respiratory failure appears reason-
able when patients are closely monitored for worsening 
respiratory distress. World Health Organization COVID-19 
guidelines and others recommend avoiding high flow nasal 
cannula use in patients with severe or worsening hypercap-
nia, hemodynamic instability, multiorgan failure, or altered 
mental status.49,50
Although guidelines recommend the use of noninvasive 
positive pressure ventilation in the management of acute 
respiratory failure due to cardiogenic pulmonary edema 
and in patients with chronic obstructive pulmonary dis-
ease (COPD) exacerbation leading to respiratory acidosis, 
no recommendations have been made regarding the use of 
noninvasive positive pressure ventilation in ARDS.60 The 
use of noninvasive positive pressure ventilation in patients 
with ARDS has been evaluated in several large trials. A 
recent study reported a high (greater than 40%) rate of non-
invasive positive pressure ventilation failure leading to inva-
sive mechanical ventilation in patients with moderate to 
severe ARDS.61 In this study, noninvasive positive pressure 
ventilation failure was associated with increased mortality, 
as was the use of noninvasive positive pressure ventilation in 
patients with more severe ARDS (Pao
2
/Fio
2
 less than 150 
mmHg).61 Several authors have suggested that the increased 
mortality observed when noninvasive positive pressure ven-
tilation is used in patients with more severe ARDS and in 
those who ultimately require invasive mechanical ventila-
tion may be explained by noninvasive positive pressure ven-
tilation delaying time to a needed intubation, and from lung 
injury caused by uncontrolled high tidal volumes with non-
invasive positive pressure ventilation.58,60,62 There are lim-
ited data to suggest that when noninvasive positive pressure 
ventilation is delivered via helmet to patients with ARDS, 
failure rates and mortality may be lower than when a con-
ventional noninvasive positive pressure ventilation facemask 
is used. While a helmet mask may be additionally beneficial 
from an infection control perspective, this intervention is 
not widely available.63
Experience from the 2009 H1N1 influenza epidemic 
and the Middle East respiratory syndrome–related corona-
virus epidemic also informs the recommendations for use 
of noninvasive positive pressure ventilation in COVID-19. 
A large observational study of H1N1 patients reported a 
greater than 50% noninvasive positive pressure ventilation 
failure rate and increased mortality in those patients who 
failed initial noninvasive positive pressure ventilation and 
required invasive mechanical ventilation.64 An observational 
study of the treatment of patients with Middle East respira-
tory syndrome–related coronavirus reported a greater than 
90% failure rate with the use of noninvasive positive pres-
sure ventilation.65
Based on the best available data, the use of noninvasive 
positive pressure ventilation as an initial strategy for the 
treatment of COVID-19–associated ARDS is likely reason-
able in the subset of patients with mild ARDS, those in 
whom COPD exacerbation or heart failure may also be 
contributing to respiratory distress, and when the patient is 
closely monitored for improvement or worsening respira-
tory distress.49,50
There is substantial concern that using noninvasive 
positive pressure ventilation or high flow nasal cannula in 
patients with viral respiratory illness results in increased 
production of aerosolized virus particles, creating a risk for 
healthcare workers or contaminating the clinical environ-
ment. While multiple studies from the 2003 SARS epidemic 
have identified participation in tracheal intubation as a risk 
factor for viral spread to healthcare workers, noninvasive 
ventilation was only identified as a risk factor in two small 
studies not considered robust enough to establish the risk 
of transmission in a 2012 meta-analysis.66–68 Experimental 
studies of exhaled air dispersion by mannequins in isolation 
rooms using conventional low flow nasal cannula, high flow 
nasal cannula, and continuous positive airway pressure with 
nasal pillows or full facemask, demonstrated greater exhaled 
air dispersion with conventional low flow nasal cannula at 5 
l/min (up to 1 m from the patient’s face) as compared with 
either high flow nasal cannula or continuous positive airway 
pressure.69,70 The authors postulated that lower exhaled air 
dispersion from high flow nasal cannula or continuous pos-
itive airway pressure masks could be related to tighter fit to 
the face with these modalities, and also that the humidified 
air generated by these modalities could result in exhalation 
of larger droplets with a shorter trajectory due to gravity.70 
The use of a full noninvasive positive pressure ventilation 
facemask might also prevent spread of aerosolized drop-
lets in a patient who is sneezing or coughing.53 Thus, there 
is a risk that any method of oxygen delivery to a patient 
with COVID-19–associated respiratory distress can result 
in spread of virus-containing exhaled air, especially if the 
mask is poorly fitted or leaking, but the concern that use of 
noninvasive positive pressure ventilation or high flow nasal 
cannula specifically leads to worse environmental contami-
nation is not substantiated by the current available evidence. 
Patients receiving any supplemental oxygen therapy should 
be cared for in airborne isolation rooms whenever possible, 
with staff using full contact, droplet, and airborne isolation 
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precautions.51,71 Providers should be aware that coronavi-
ruses can remain infectious on inanimate surfaces for up to 
9 days, and all surfaces and equipment used for SARS-2-
CoV–infected patients should be carefully disinfected with 
70% or greater ethanol for small surfaces or 0.1% or greater 
sodium hypochlorite for larger surfaces.72
Regardless of the choice of initial oxygen therapy for 
patients with COVID-19–associated respiratory failure, 
these patients should be closely monitored for deterioration 
and intubated promptly to avoid the need for an emergent 
intervention.51,73 Experience from the 2003 SARS epi-
demic suggests that intubation is a time when healthcare 
workers are at high risk for viral transmission from infected 
patients (odds ratio, 6.6).66 It should be noted, however, that 
several of the healthcare providers who contracted SARS 
while intubating patients were wearing only standard sur-
gical facemasks at the time of intubation, and there is no 
strong evidence to link intubation with risk of transmission 
of virus to healthcare workers when proper airborne pre-
cautions are taken.74 Of note, while several post hoc reports 
from the 2003 SARS epidemic and emerging reports from 
this current epidemic recommend the use of higher level 
personal protective equipment such as a powered air-pu-
rifying respirators, double gloves, coveralls, foot covers, or 
hoods when performing aerosol generating procedures such 
as intubation, there does not appear to be evidence to sup-
port the superiority of these measures over standard drop-
let, contact, and aerosol precautions.66,73,75 Some have even 
suggested that the use of increasing layers of barrier precau-
tions without strong evidence to support their application 
makes patient care more challenging and could increase the 
risk of contamination during lengthy and complex personal 
protective equipment removal procedures.74,75 Application 
of full barrier precautions has been reported to take at least 
5 min, and ideally should not be performed emergently.74
When endotracheal intubation is indicated, the World 
Health Organization COVID-19 clinical guidelines suggest 
that it be performed by an experienced provider using air-
borne precautions.49 The guidelines also recommend the use 
of any modality (non-rebreather mask, bag valve mask, high 
flow nasal cannula, or noninvasive positive pressure venti-
lation) for preoxygenation with 100% oxygen for 5 min, 
and the use of a rapid sequence induction when possible 
to avoid coughing or need for positive pressure breaths.49 
Additional guidelines and experiential reports from Hubei 
province largely echo these recommendations.50,51 Of note, 
data from a recent meta-analysis did not note any benefit 
from the use of high flow nasal cannula for peri-intubation 
preoxygenation as compared with usual oxygen therapy 
in patients with hypoxemic respiratory failure.76 However, 
high flow nasal cannula may be of benefit to prevent severe 
hypoxemia during intubations with prolonged apneic 
times or in patients who have very severe hypoxemia.76 See 
table 2 for additional clinical recommendations regarding 
airway management.
After intubation, management of COVID-19–associated 
respiratory failure is the same as in ARDS from other 
causes. U.S., European Union, and recently released United 
Kingdom ARDS guidelines strongly recommend the use 
of low tidal volume ventilation (4 to 8 ml/kg predicted 
body weight in the U.S./European Union guidelines or less 
than 6 ml/kg in the United Kingdom guidelines, to main-
tain plateau pressures less than 30 cm H
2
0), with permissive 
hypercapnia.77,78 The U.S., European Union, and United 
Kingdom guidelines also strongly recommend the use of 
prone positioning for greater than 12 h per day in patients 
with severe (moderate-severe in United Kingdom guide-
lines) ARDS, and this recommendation is echoed in the 
World Health Organization SARS-CoV-2 guideline.77,78 
However, as prone ventilation is a resource-intensive inter-
vention where the endotracheal tube and other lines may 
become displaced, it is only recommended when there are 
sufficient human resources and expertise within the med-
ical center for this intervention to be performed safely.49
The World Health Organization guidelines for the man-
agement of COVID-19 echo the United Kingdom ARDS 
guidelines in recommending a conservative fluid man-
agement strategy for patients without evidence of tissue 
hypoperfusion.49,78 While both the U.S./European Union 
and United Kingdom ARDS guidelines weakly recom-
mend the use of higher PEEP in moderate to severe ARDS 
and the United Kingdom guidelines weakly recommend 
the use of neuromuscular blockade by continuous infusion 
early in moderate to severe ARDS, recent clinical trials 
challenge these recommendations, and thus, various com-
ponents of best clinical practice for ARDS remain unclear 
at this time.79,80 A large multicenter trial of patients ran-
domized to receive either a conventional low PEEP venti-
lation strategy or a titrated PEEP strategy resulting in high 
PEEP combined with lung recruitment maneuvers found 
increased mortality in the higher PEEP and lung recruit-
ment maneuver arm.81 Regarding the use of neuromuscular 
blockade, a recent multicenter randomized trial found no 
mortality benefit with its use in early moderate to severe 
ARDS, and more adverse cardiovascular events in the paral-
ysis arm of the study.82 With these trials in mind, the World 
Health Organization guidelines suggest cautious use of 
higher PEEP in moderate or severe ARDS, but not routine 
use of neuromuscular blockade.49
In patients with refractory hypoxemia despite lung pro-
tective ventilation with best practices, there are limited data 
to guide effectiveness of the use of extracorporeal membrane 
oxygenation. The United Kingdom ARDS guidelines weakly 
recommend consideration of extracorporeal membrane 
oxygenation in patients with severe ARDS and refractory 
hypoxemia, although this recommendation was published 
before the results of a randomized controlled trial of extra-
corporeal membrane oxygenation for ARDS, which was 
stopped early due to lack of a statistically significant mortality 
benefit between the extracorporeal membrane oxygenation 
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Table 2. Collected Practical Recommendations from Published Literature to Guide Anesthesiologists Caring for Patients with 
COVID-19
Infection control •   Strict adherence to universal precautions at all times.49
•   Perform practice drills to familiarize providers with appropriate procedures for donning/doffing personal protective equipment during both 
nonemergent and emergent situations.
•   Perform crisis management simulation to help providers prepare for intubation and code blue events in isolation rooms.
Intubation •   Do not delay intubation in patients with worsening respiratory failure, avoid emergent situations where personal protective equipment must 
be applied in haste.51,53
•   For intubations either in the operating room or ICU, wear at least a gown, N95 or higher mask, cap, face shield, and gloves. Some sources 
suggest powered air-purifying respirators, double gloves, boots, and coveralls.51,52,71
•   If using a powered air-purifying respirator, consider an N95 under it to minimize risk of contamination when removing the powered air-purify-
ing respirator.51
•   Have a colleague or personal protective equipment champion check proper personal protective equipment application before entering the 
patient’s room or operating room.
•   Consider writing provider names on gowns or hoods (if worn) to make identification easier.52
•   Consider the assembly of intubation kits with all needed supplies in advance, to avoid multiple entries/exits to an isolation room, and delays 
in obtaining necessary supplies.51,54
•   Consider reviewing an intubation plan with all providers before entering the patient room.
•   Have the minimal number and most experienced personnel in the room whenever possible.50,51,71,73
•   Use disposable equipment whenever possible.73
•   Preoxygenate for 5 min with 100% oxygen to avoid manual ventilation if possible.49
•   When possible, use a rapid sequence or modified rapid sequence induction to avoid bag mask ventilation of the patient.49
•   Consider inserting a laryngeal mask airway if prolonged need to mask the patient is anticipated.71
•   Rocuronium may be preferred to succinylcholine as paralytic in rapid sequence induction to avoid the potential for paralysis to wear off and 
the patient to cough if the intubation procedure is prolonged.71
•   Attach a high efficiency hydrophobic filter between the mask or endotracheal tube and bag.51,73
•   Avoid awake fiberoptic intubation if possible to decrease patient coughing during intubation.73
•   Use video laryngoscopy where available to increase the distance between the patient and intubating provider.51
•   Put the cuff up immediately after intubation of the trachea.71
•   Monitor intubation success with capnography—use of personal protective equipment may make auscultation with a stethoscope difficult or 
impossible.51,52,71
•   Consider the use of ultrasound or chest radiograph to confirm tracheal rather than bronchial intubation, as auscultation may be difficult or 
impossible.51
•   Note that standard 0.05% sodium hypochlorite was not as effective at inactivating coronavirus as 0.1% (double concentration) sodium 
hypochlorite.72
•   Clearly label rooms and hot zones with patients with COVID-19 so that providers know to put on appropriate personal protective equipment.73
•   Have a colleague or personal protective equipment champion check proper personal protective equipment removal after exiting the patient’s 
room.
Oxygen and  
ventilator 
management
•   Use noninvasive positive pressure ventilation, high flow nasal cannula, or mechanical ventilation only in single airborne isolation rooms.51
•   Consider having patients on supplementary oxygen via nasal cannula wear a surgical mask over the tubing.51
•   Consider the use of in-line suction systems or minimize suctioning if possible.49
•   Frequently empty condensation from tubing lines.53
•   Consider using medications such as dexmedetomidine, lidocaine, or remifentanil on extubation to minimize coughing.
Pre/postoperative  
care units
•   Designate an isolated COVID-19 holding/recovery area, ideally a dedicated room with negative pressure ventilation.51,52
•   Consider requiring all patients and providers to wear masks in the perioperative setting.52
•   Consider having all patients transported to and from operating rooms wear a surgical mask or N95.52
•   Consider dedicated hallways and patient transport routes for COVID-19 patients, if possible.52
Operating room •   Consider a dedicated operating room for patients with COVID-19, ideally with an anteroom and both with negative pressure. If no negative 
pressure operating rooms, work with engineering to turn off the positive-pressure system.51
•   Or, consider using a negative pressure isolation ICU room as an operating room if surgery is necessary on a patient with COVID-19.106
•   Use a dedicated anesthesia machine with high efficiency hydrophobic filters on the inspiratory and expiratory limbs of the circuit. Change the 
filters every 3 to 4 h during operative cases.52
•   Consider general anesthesia for patients to reduce the risk of coughing, or if not intubated have patients wear a surgical mask or N95.
•   Minimize staff and handoffs.
•   Operating room and ventilator must be completely cleaned after use. Pay special attention to the patient chart, pens, and phones when 
disinfecting.
Code blue •   Create modular code packs to bring into rooms to prevent contamination of code blue carts and make needed equipment easily accessible in 
an isolation room during an emergency.51
•   Consider implementing a special designation, such as “protected code blue,” to distinguish a code blue in a patient with COVID-19 from other 
code events.51
•   Designated a “protected code blue coach” who makes sure all care providers entering and exiting the room follow safe don/doff procedures 
with personal protective equipment.51
Perioperative clinic •   In the case of an epidemic, consider screening preoperative patients for fever, and sending those who are ill or febrile to the emergency room 
or home as appropriate.
•   Consider having providers use contact, droplet, and potentially aerosol transmission precautions when seeing patients in the preoperative 
clinic.
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group and the medical management group.78,79,83 However, a 
re-analysis of the data from this trial, as well as a meta-analysis 
incorporating these new trial data, suggest that extracorpo-
real membrane oxygenation may provide a mortality bene-
fit in patients with severe ARDS.84 In a small case-control 
series during the Middle East respiratory syndrome–related 
coronavirus outbreak, use of extracorporeal membrane oxy-
genation for refractory hypoxemia was associated with lower 
in-hospital mortality.85 Considering these data, it may be rea-
sonable to refer COVID-19 patients with refractory hypox-
emia despite lung protective ventilation for extracorporeal 
membrane oxygenation in centers with the expertise and 
resources to properly manage such complex patients.49,50
If patients with COVID-19–associated respiratory fail-
ure develop superimposed septic shock, adherence to stan-
dard sepsis treatment protocols is advised.49 Additional, 
nonevidence-based recommendations for the management 
of COVID-19–associated respiratory failure have been pro-
mulgated by a variety of guidelines and published sources, 
largely focusing on minimizing viral spread to healthcare 
workers or the environment. These recommendations 
include minimizing ventilator disconnections, the use of 
in-line catheters for airway suction,49 using a high efficiency 
hydrophobic filter between the patient and the breathing 
circuit,51,73 and avoiding the use of nebulized medications 
in favor of metered dose inhalers if bronchodilators are 
indicated.51 A collected list of practical recommendations to 
guide anesthetic and critical care management of COVID-
19 patients is found in table  2. Table  3 provides a list of 
organizations offering updated guidelines and resources for 
providers caring for patients with COVID-19.
Therapeutic Interventions
While there are no drugs specifically approved for treatment 
of COVID-19, there are multiple ongoing clinical trials and 
a number of drugs that show promise. SARS-CoV-2 is an 
RNA virus, like human immunodeficiency virus (HIV) and 
Ebola, and molecules developed for other RNA viruses may 
be useful targets (fig. 2). In particular, remdesivir is a nucle-
otide analog developed for use with Ebola infection. The 
drug inhibits the RNA-dependent RNA polymerase used 
by coronavirions to replicate their genome.86 Based on in 
vitro evidence of effectiveness, the manufacturer initiated two 
phase 3 clinical trials of the use of remdesivir in COVID-19 
(trial Nos. NCT04292730 and NCT04292899). Similar trials 
in severe and moderate cases of COVID-19 are underway 
in China (trial Nos. NCT04252664 and NCT04257656). 
Remdesivir is also the initial treatment arm in an adaptive 
clinical trial sponsored by the National Institute of Allergy and 
Infectious Diseases (trial No. NCT04280705). This adaptive 
trial will be actively modified to add novel drugs of interest 
and to replace the control arm with the current best supported 
regimen. Interestingly, the antimalaria drug chloroquine has 
also been shown to inhibit SARS-CoV-2 at micromolar con-
centrations. This agent, which blocks virus infection both at 
entry and postentry stages, has been used in therapeutic and 
prophylactic regimens for more than 70 yr, so its safety pro-
file, including prominent neurologic and gastrointestinal side 
effects, is well known.87 Among its possible mechanisms of 
action are altering the pH of endosomes and directly modi-
fying angiotensin converting enzyme-2.88 Compared with a 
historical control cohort, SARS-CoV-1 patients treated with 
combination lopinavir/ritonavir had significantly lower risk 
of ARDS or death.89 The combination of lopinavir/ritonavir 
has been used in COVID-19 cases as well, based on these 
SARS data and in vitro effectiveness.90,91 However, clinical 
effectiveness remains unproven, and providers should be cog-
nizant of the known side effect profile for this medication and 
monitor for hepatotoxicity, hyperglycemia, and arrythmias.92 
An ongoing clinical trial is comparing patients randomized 
to lopinavir/ritonavir and the viral fusion inhibitor arbidol 
(trial No. NCT04252885). As the optimal regimen remains to 
be determined, affected patients should consider enrolling in 
clinical trials whenever available.
World Health Organization and Centers for Disease 
Control and Prevention recommendations49,93 discourage 
the use of corticosteroids, given the risk for precipitating 
infectious and noninfectious complications, such as second-
ary bacterial infections or hyperglycemia. Further, in Middle 
East respiratory syndrome–related coronavirus patients, ste-
roid therapy was associated with delayed viral clearance and 
no improvement in survival.94 However, it can be difficult 
to account for the bias that sicker patients are more likely 
Table 3. Selected Online COVID-19 Resources for Anesthesiologists
American Society of Anesthesiologists https://www.asahq.org/about-asa/governance-and-committees/asa-committees/
committee-on-occupational-health/coronavirus
Anesthesia Patient Safety Foundation https://www.apsf.org/news-updates/perioperative-considerations-for-the-2019-novel-coronavirus-covid-19/
Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html
Johns Hopkins (live map of global cases) https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
University of Toronto https://www.anesthesia.utoronto.ca/news/coronavirus-and-safety-precautions
World Federation of Societies of Anesthesiologists https://www.wfsahq.org/resources/coronavirus
World Health Organization https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when- 
novel-coronavirus-(ncov)-infection-is-suspected
All websites were accessed on March 7, 2020.
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to receive steroids. In ARDS, despite multiple randomized 
controlled studies of corticosteroids, the benefits of corti-
costeroids remain equivocal.95 It is likely the benefits are 
greater for select ARDS patients, such as those early in the 
disease course or those with superimposed septic shock.96
COVID-19 patients have multiple distinct radiologic pat-
terns: diffuse ground glass, reticulation, consolidation sugges-
tive of pneumonitis, diffuse alveolar damage, and organizing 
pneumonia.46 In cryptogenic organizing pneumonia, steroid 
administration has been suggested to prevent progression to 
hypoxemic respiratory failure in case series.97 At the same 
time, the requirement for steroids has been shown to be less 
relevant for organizing pneumonia with an identified cause, 
as in COVID-19.97 Compared with steroids, patients treated 
with macrolides for mild cryptogenic organizing pneu-
monia also demonstrated symptom resolution, albeit with 
higher relapse rates.98 In case series of COVID-19 patients, 
steroids and macrolides were commonly used, but we lack 
data as to their effectiveness.24,47 In a retrospective analysis, 
which could be confounded by indication, steroid therapy 
was associated with decreased risk of death in patients with 
ARDS and COVID-19.99  Specific studies in COVID-19 
patients are needed to determine whether corticosteroids or 
macrolides could be beneficial in a subset of patients, such as 
those with organizing pneumonia patterns.
Conclusions
In the face of this rapidly emerging global threat, there are sev-
eral reasons for optimism about future control. As described 
above, a number of antiviral drugs have shown promise in 
vitro. Even a partially effective antiviral could allow sufficient 
reduction in viral load so that the immune system can recover 
and respond to prevent lethal disease. There is even potential 
that antivirals could be used in chemoprophylaxis to prevent 
transmission in recently exposed individuals. While resistance 
to antivirals developed quickly in patients with HIV, studies 
in coronaviruses suggest this might be less of a problem.100 
Similarly, while HIV readily evades cellular and humoral 
immunity, sharply limiting vaccination approaches,101 SARS-
CoV infection appeared to induce broad and long-lasting 
immunity with less evidence of immune escape.102 Thus, it 
is likely that as COVID-19 evolves, physicians will have a 
variety of therapeutic and vaccination options to minimize 
morbidity and mortality. Until these arrive, anesthesiologists 
will be called upon to provide supportive care while mini-
mizing the risk of viral transmission to themselves and others.
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